Trump Stock Purchases and the Retatrutide "Compassionate Use" Ethics Controversy
The intersection of federal health policy, political influence, and Eli Lilly’s pipeline has erupted into a major controversy. In late June 2026, investigative reports revealed that a single 79-year-old patient was granted highly unusual, early access to Eli Lilly's unapproved, experimental triple-hormone agonist retatrutide under the FDA's "compassionate use" (expanded access) program. The timing, age, and nature of the request have led to intense congressional scrutiny and public speculation that the recipient is President Donald Trump.
This development follows earlier federal ethics disclosures showing that Donald Trump purchased between $415,000 and $680,000 in Eli Lilly stock in early 2026, just as his administration began advancing highly favorable GLP-1 policies, such as the Medicare GLP-1 Bridge Program.
The Unusual Expanded Access Case
According to a barebones public filing on ClinicalTrials.gov and reports by STAT News and Ars Technica, the expanded access request was submitted in April 2026 on behalf of a single 79-year-old male (President Trump turned 80 on June 14, 2026).
The request was filed by Ranganath Muniyappa, a senior clinician at the National Institutes of Health (NIH), for a patient with:
- Refractory obesity
- Obstructive sleep apnea
- Pulmonary hypertension
The clinical file noted that the patient had spent a year on Eli Lilly's tirzepatide (Mounjaro/Zepbound) but achieved only "moderate" weight loss, and was deemed an unsuitable candidate for bariatric surgery due to age and comorbidities.
Multiple bioethics and regulatory experts have flagged the case as highly irregular. The FDA's compassionate use program is legally reserved for "serious or immediately life-threatening" conditions where no alternative therapies exist. Obesity and sleep apnea, while serious, do not typically meet this bar, especially when other approved therapies are widely available. Furthermore, the public listing was highly obscured, omitting basic descriptive information.
"Only people in the know would be able to find this [notice], using the drug name. There is something very wrong with the way this is listed because no one would know what it is from the listing, or what it’s for." — Richard Klein, former director of the FDA's Patient Liaison Program, quoted in Ars Technica
Political Fallout and Administration Denials
The revelation has triggered immediate political blowback. Democratic lawmakers, including Senator Maggie Hassan (D-N.H.) and Representative Ted Lieu (D-Calif.), have formally pressed the Department of Health and Human Services (HHS) and HHS Secretary nominee RFK Jr. for answers, questioning whether a well-connected political figure received preferential treatment.
The White House has actively pushed back against the reports. White House spokesperson Kush Desai issued a social media statement stating that the application "was not for the President." However, journalists noted that both HHS and the White House repeatedly refused to answer direct inquiries before publication, and the medical details of the request (such as pulmonary hypertension) do not match the President's publicly released physical examination summaries.
Investment and Policy Implications
For investors, this controversy highlights the deep political ties and regulatory tailwinds surrounding Eli Lilly. Whether or not the President was the specific recipient, the rapid, highly irregular FDA and NIH coordination to grant single-patient access to Lilly's most valuable clinical asset underscores the company's formidable influence in Washington. It also highlights the extreme, unprecedented demand for retatrutide, which is widely viewed as the "holy grail" of the next-generation obesity pipeline.